Sarepta Therapeutics Inc. CEO Doug Ingram told Wall Street that the firm "has couple of things we've got to get done very soon and report back to you on," given early results in the first three-patient cohort of the MYO-101 study in patients with limb-girdle muscular dystrophy (LGMD) known as LGMD2E – strongly positive results that triggered an early exercise of the option to acquire Myonexus Therapeutics Inc. for $165 million.